Senti Biosciences, Inc. (SNTI)

In the past six months, Senti Biosciences' stock has experienced a significant decline of 42.78%, and over the past year, the share price decreased by 74.61%. A notable event impacting the stock was a 1-for-10 reverse stock split that occurred on Thursday, July 18, 2024. Positive news that has impacted the stock includes the announcement of updated positive clinical data from the ongoing Phase 1 trial for SENTI-202 in relapsed or refractory acute myeloid leukemia patients, demonstrating deep, MRD negative, durable complete remissions and a favorable safety profile. Furthermore, Senti Bio received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for SENTI-202 in the treatment of adults with relapsed or refractory acute myeloid leukemia. In December 2022, the company announced pipeline prioritization to focus on logic-gated cell therapies.

As a clinical-stage biotechnology company focused on developing cell and gene therapies, Senti Biosciences' products and services are not subject to typical consumer demand seasonality. The demand for its therapeutic candidates is driven by clinical trial progress, regulatory milestones, and the prevalence of the diseases it aims to treat, rather than seasonal consumer patterns.

Senti Biosciences, Inc. (SNTI) is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, operating within the Health Care sector, specifically in the Biotechnology and Pharmaceutical industries. The company leverages a proprietary gene circuit platform technology to engineer immune cells with enhanced capabilities to precisely identify and target disease sites, respond to complex biological signals, and exhibit controlled therapeutic activity. Its lead product candidates include SENTI-202, a logic-gated off-the-shelf CAR-NK cell therapy designed for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia, and SENTI-301A, an off-the-shelf CAR-NK cell therapy aimed at treating solid tumors and hepatocellular carcinoma. The company also has preclinical programs, including a solid tumor cell therapy program and partnered programs related to gene therapies for tissue-directed targets and cell therapies for regenerative medicines.

Senti Biosciences, Inc. is headquartered in South San Francisco, California. The company has also established a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. for the clinical development of SENTI-301A, indicating an international partnership.

In the past year, Senti Biosciences has received a generally positive brand reputation from analysts, with a consensus rating ranging from "Moderate Buy" to "Very Bullish." The company's average rating score is 2.83, based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating, and the average price target from analysts is $9.00. Key events that have positively affected Senti Biosciences' reputation include the announcement of positive clinical data from its SENTI-202 trial and the receipt of FDA Regenerative Medicine Advanced Therapy (RMAT) designation for SENTI-202.

Senti Biosciences (NASDAQ: SNTI) is primarily owned by institutional shareholders and insiders. Institutional shareholders own approximately 22.30% to 25.70% of the company's stock, while Senti Biosciences insiders own a substantial 65.85% to 97.70%. Retail investors hold a smaller portion, around 0.00% to 11.72%. Major institutional owners include NEA Management Company, LLC, Nantahala Capital Management, LLC, Vanguard Group Inc, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Geode Capital Management, Llc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Citadel Advisors Llc, XTX Topco Ltd, BlackRock, Inc., and IWC - iShares Micro-Cap ETF. Among individual and insider owners, Celadon Partners Spv 24 is the largest, holding 9.78 million shares, representing 37.19% of the company. Other significant insider owners include Omid Farokhzad, Bayer Healthcare LLC, Philip J. Lee, Timothy K. Lu (CEO), and Mostafa Ronaghi.